Document is current

Article History

Received: 30 December 2025

Accepted: 23 February 2026

First Online: 8 March 2026

Declarations

:

: The studies involving humans were approved by Shandong Provincial Hospital Affiliated to Shandong First Medical University. The studies were conducted in accordance with the local legislation and institutional requirements. The approved title is “Real-World Single-Center Analysis of Efficacy and Safety in Newly Diagnosed Marginal Zone Lymphoma”, with approval number NSFC: NO.2024-84 and approval date January 1, 2024.Written informed consent for participation in this study was provided by the participants’ legal guardians/next of kin. Written informed consent was obtained from the minor(s)’legal guardian/ next of kin for the publication of any potentially identifiable images or data included in this article.

: The authors declare no competing interests.

: The patients provided written informed consent for publication, authorizing the use of their clinical data for publication.